Large intraindividual variability of olanzapine serum concentrations in adolescent patients

Therapeutic Drug Monitoring

Volumn 30, Issue 1, 2008, Pages 108-112

  Bachmann, Christian J ^a   Haberhausen, Michael ^a   Heinzel Gutenbrunner, Monika ^a   Remschmidt, Helmut ^a   Theisen, Frank M ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Adolescents; Interindividual variability; Olanzapine; Therapeutic drug monitoring

Indexed keywords

OLANZAPINE;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; ARTICLE; AUTISM; BIPOLAR DISORDER; BODY MASS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; EMOTIONAL DISORDER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROSIS; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHOOL CHILD; SOMATOFORM DISORDER;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 38549114148     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181633429     Document Type: Article

References (28)

1. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396-1404.
2. Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol. 2000;20:220-225.
3. Kelly DL, Love RC, MacKowick M, et al. Atypical antipsychotic use in a state hospital inpatient adolescent population. J Child Adolesc Psychopharmacol. 2004;14:75-85.
4. Findling RL, McNamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry. 2004;65(Suppl 6):30-44.
5. Mehler C, Wewetzer C, Schulze U, et al. Olanzapine in children and adolescents with chronic anorexia nervosa: a study of five cases. Eur Child Adolesc Psychiatry. 2001;10:151-157.
6. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68:224-236.
7. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177-193.
8. Baumann P, Hiemke C, Ulrich S, et al. Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
9. Theisen FM, Haberhausen M, Schulz E, et al. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: Effects of dose, diagnosis, age, gender, smoking, and comedication. Ther Drug Monit. 2006;28:750-759.
10. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46-53.
11. Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-dimethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24:518-526.
12. SPSS for Windows [computer program]. Version 14.0. Chicago: SPSS Inc; 2006.
13. SAS [computer program]. Version 8. Cary, NC: SAS Institute, Inc; 1999.
14. Singer JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat. 1998;24:322-354.
15. Aravagiri M, Ames D, Wirshing WC, et al. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit. 1997;19:307-313.
16. Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit. 2006;28:744-749.
17. Darby JK, Pasta DJ, Elfand L, et al. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol. 1997;17:478-484.
18. Schulz E, Fleischhaker C, Remschmidt H. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. J Child Adolesc Psychopharmacol. 1996;6:119-131.
19. Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111:1416-1421.
20. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Drug therapy: developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.
21. Aranda JV, Collinge JM, Zinman R, et al. Maturation of caffeine elimination in infancy. Arch Dis Child. 1979;54:946-949.
22. Lambert GH, Schoeller DA, Kotake AN, et al. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Pharmacol Ther. 1986;9:375-388.
23. Haslemo T, Eikeseth PH, Tanum L, et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006;62:1049-1053.
24. Simon T, Becquemont L, Hamon B, et al. Variability of cytochrome P450 activity over time in young and elderly healthy volunteers. Br J Clin Pharmacol. 2001;52:601-604.
25. Hägg S, Spigset O, Lakso HÅ , et al. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol. 2001;57:493-497.
26. Gerlach M, Hünnerkopf R, Rothenhöfer S, et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacophychiatry. 2007;40:72-76.
27. Lu ML, Lane HY, Lin SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry. 2004;65:766-771.
28. Fellows L, Ahmad F, Castle DJ, et al. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Ther Drug Monit. 2003;25:682-689.